For complete information about the report, please visit our website
Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature biotech company on the strength of its innovative platforms to develop biologics. Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are the future drivers. MOR enter into out-licensing deal with CELG for jointly development of MOR-202 (HuCAL antibody targeting CD38) for a total value of €698.8m. CELG strong presence in hematological malignancy further enhances the value with possible expansion in other leukemia’s....... For more detail, please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.
No comments:
Post a Comment